Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments

被引：76

作者：

Gisbert, J. P. ^{[1
]}

Romano, M. ^{[2
]}

Gravina, A. G. ^{[3
]}

Solis-Munoz, P. ^{[4
]}

Bermejo, F. ^{[5
]}

Molina-Infante, J. ^{[6
]}

Castro-Fernandez, M. ^{[7
,8
]}

Ortuno, J. ^{[8
,9
]}

Lucendo, A. J. ^{[10
]}

Herranz, M. ^{[11
]}

Modolell, I. ^{[12
]}

del Castillo, F. ^{[13
]}

Gomez, J. ^{[14
]}

Barrio, J. ^{[15
]}

Velayos, B. ^{[16
]}

Gomez, B. ^{[17
]}

Dominguez, J. L. ^{[18
]}

Miranda, A. ^{[2
]}

Martorano, M. ^{[3
]}

Algaba, A. ^{[3
]}

Pabon, M. ^{[7
,8
]}

Angueira, T. ^{[10
]}

Fernandez-Salazar, L. ^{[16
]}

Federico, A. ^{[2
]}

Marin, A. C. ^{[1
]}

McNicholl, A. G. ^{[1
]}

机构：

[1] Hosp Univ Princesa, Gastroenterol Unit, Inst Invest Sanitaria Princesa, CIBEREHD, Madrid, Spain

[2] Seconda Univ Napoli, Naples, Italy

[3] Osped PO Immacolata, Sapri, Italy

[4] Angloamer Med Unit, Madrid, Spain

[5] Hosp Fuenlabrada, Madrid, Spain

[6] Hosp San Pedro de Alcantara, Caceres, Spain

[7] Hosp Valme, Seville, Spain

[8] CIBEREHD, Madrid, Spain

[9] Hosp La Fe, E-46009 Valencia, Spain

[10] Hosp Gen Tomelloso, Ciudad Real, Spain

[11] Hosp N Sra Sonsoles, Avila, Spain

[12] Consorci Sanitari Terrassa, Barcelona, Spain

[13] Hosp Don Benito, Badajoz, Spain

[14] Hosp Gregorio Maranon, Madrid, Spain

[15] Hosp Rio Hortega, Valladolid, Spain

[16] Hosp Clin, Valladolid, Spain

[17] Hosp Quiron Sagrado Corazon, Seville, Spain

[18] Alto Guadalquivir, Jaen, Spain

来源：

ALIMENTARY PHARMACOLOGY & THERAPEUTICS | 2015年 / 41卷 / 08期

关键词：

CONCOMITANT THERAPY; SEQUENTIAL THERAPY; ERADICATION; INFECTION; RESISTANCE; EFFICACY; SUBCITRATE; CLARITHROMYCIN; METAANALYSIS; ANTIBIOTICS;

D O I：

10.1111/apt.13128

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

BackgroundThe most commonly used second-line Helicobacter pylori eradication regimens are bismuth-containing quadruple therapy and levofloxacin-containing triple therapy, both offering suboptimal results. Combining bismuth and levofloxacin may enhance the efficacy of rescue eradication regimens. AimsTo evaluate the efficacy and tolerability of a second-line quadruple regimen containing levofloxacin and bismuth in patients whose previous H. pylori eradication treatment failed. MethodsThis was a prospective multicenter study including patients in whom a standard triple therapy (PPI-clarithromycin-amoxicillin) or a non-bismuth quadruple therapy (PPI-clarithromycin-amoxicillin-metronidazole, either sequential or concomitant) had failed. Esomeprazole (40mg b.d.), amoxicillin (1g b.d.), levofloxacin (500mg o.d.) and bismuth (240mg b.d.) was prescribed for 14days. Eradication was confirmed by C-13-urea breath test. Compliance was determined through questioning and recovery of empty medication envelopes. Incidence of adverse effects was evaluated by questionnaires. Results200 patients were included consecutively (mean age 47years, 67% women, 13% ulcer). Previous failed therapy included: standard clarithromycin triple therapy (131 patients), sequential (32) and concomitant (37). A total of 96% took all medications correctly. Per-protocol and intention-to-treat eradication rates were 91.1% (95%CI=87-95%) and 90% (95%CI=86-94%). Cure rates were similar regardless of previous (failed) treatment or country of origin. Adverse effects were reported in 46% of patients, most commonly nausea (17%) and diarrhoea (16%); 3% were intense but none was serious. ConclusionsFourteen-day bismuth- and levofloxacin-containing quadruple therapy is an effective (90% cure rate), simple and safe second-line strategy in patients whose previous standard triple or non-bismuth quadruple (sequential or concomitant) therapies have failed.

引用

页码：768 / 775

页数：8

共 50 条

[1] Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy
Song, Zhiqiang
Zhou, Liya
Zhang, Jianzhong
He, Lihua
Bai, Peng
Xue, Yan
DIGESTIVE AND LIVER DISEASE, 2016, 48 (05) : 506 - 511
[2] Second-line bismuth-containing quadruple therapy for Helicobacter pylori eradication and impact of diabetes
Kim, Sung Eun
Park, Moo In
Park, Seun Ja
Moon, Won
Kim, Jae Hyun
Jung, Kyoungwon
Kim, Hae Koo
Dal Lee, Young
WORLD JOURNAL OF GASTROENTEROLOGY, 2017, 23 (06) : 1059 - 1066
[3] Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple "sequential" or "concomitant" treatment to eradicate H. pylori infection
Gisbert, Javier P.
Molina-Infante, Javier
Marin, Alicia C.
Vinagre, Gemma
Barrio, Jesus
McNicholl, Adrian Gerald
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2013, 48 (06) : 652 - 656
[4] Moxifloxacin-containing triple therapy after non-bismuth quadruple therapy failure for Helicobacter pylori infection
Lim, Ji Hyun
Lee, Dong Ho
Lee, Seong Tae
Kim, Nayoung
Park, Young Soo
Shin, Cheol Min
Song, In Sung
WORLD JOURNAL OF GASTROENTEROLOGY, 2015, 21 (46) : 13124 - 13131
[5] Comparison of Helicobacter pylori Eradication Rates of 2-Week Levofloxacin-Containing Triple Therapy, Levofloxacin-Containing Bismuth Quadruple Therapy, and Standard Bismuth Quadruple Therapy as a First-Line Regimen
Aksoy, Evrim Kahramanoglu
Sapmaz, Ferdane Pirincci
Goktas, Zeynep
Uzman, Metin
Nazligul, Yasar
MEDICAL PRINCIPLES AND PRACTICE, 2017, 26 (06) : 523 - 529
[6] Moxifloxacin-containing triple therapy after non-bismuth quadruple therapy failure for Helicobacter pylori infection
Ji Hyun Lim
Dong Ho Lee
Seong Tae Lee
Nayoung Kim
Young Soo Park
Cheol Min Shin
In Sung Song
World Journal of Gastroenterology, 2015, (46) : 13124 - 13131
[7] Risk factors of rescue bismuth quadruple therapy failure for Helicobacter pylori eradication
Lee, Jung Won
Kim, Nayoung
Nam, Ryoung Hee
Lee, Sun Min
Soo In, Choi
Kim, Jung Mogg
Lee, Dong Ho
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 (04) : 666 - 672
[8] Third-Line Rescue Therapy with Bismuth-Containing Quadruple Regimen After Failure of Two Treatments (with Clarithromycin and Levofloxacin) for H-pylori Infection
Gisbert, J. P.
Perez-Aisa, A.
Rodrigo, L.
Molina-Infante, J.
Modolell, I.
Bermejo, F.
Castro-Fernandez, M.
Anton, R.
Sacristan, B.
Cosme, A.
Barrio, J.
Harb, Y.
Gonzalez-Barcenas, M.
Fernandez-Bermejo, M.
Algaba, A.
Marin, A. C.
McNicholl, A. G.
DIGESTIVE DISEASES AND SCIENCES, 2014, 59 (02) : 383 - 389
[9] Moxifloxacin-Containing Triple Therapy versus Bismuth-Containing Quadruple Therapy for Second-Line Treatment of Helicobacter pylori Infection: A Meta-Analysis
Wu, Cheng
Chen, Xiao
Liu, Jing
Li, Ming-Yang
Zhang, Zi-Qi
Wang, Zhi-Qiang
HELICOBACTER, 2011, 16 (02) : 131 - 138
[10] Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori
Gisbert, Javier P.
Calvet, Xavier
CLINICAL AND EXPERIMENTAL GASTROENTEROLOGY, 2012, 5 : 23 - 34

← 1 2 3 4 5 →